49. 全身性エリテマトーデス Systemic lupus erythematosus Clinical trials / Disease details

臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

3 trials found

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05620407 (ClinicalTrials.gov)	January 12, 2023	10/11/2022	A Study to Evaluate Effectiveness and Safety of Deucravacitinib(BMS-986165) Compared With Placebo in ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ...	Systemic Lupus Erythematosus	Drug: Deucravacitinib;Other: Placebo	Bristol-Myers Squibb	NULL	Recruiting	18 Years	75 Years	All	490	Phase 3	United States;Argentina;Australia;Brazil;Chile;Czechia;Greece;Hungary;Japan;Mexico;Peru;Poland;Portu ...
2	NCT05617677 (ClinicalTrials.gov)	January 12, 2023	8/11/2022	A Study to Assess Effectiveness and Safety of DeucravacitinibCompared With Placebo in Participants W ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ...	Systemic Lupus Erythematosus	Drug: Deucravacitinib;Other: Placebo	Bristol-Myers Squibb	NULL	Recruiting	18 Years	75 Years	All	490	Phase 3	United States;Argentina;Brazil;Bulgaria;Canada;China;Colombia;France;Germany;Hong Kong;Ireland;Italy ...
3	NCT03920267 (ClinicalTrials.gov)	March 26, 2019	27/3/2019	Long-Term Safety and Efficacy Study of Deucravacitinibin Participants With Systemic Lupus Erythemato ...	A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects Wit ...	Systemic Lupus Erythematosus	Drug: BMS-986165	Bristol-Myers Squibb	NULL	Active, not recruiting	18 Years	75 Years	All	261	Phase 2	United States;Argentina;Brazil;Canada;Colombia;Hungary;Japan;Korea, Republic of;Mexico;Poland;Romani ...

First Previous1Next Last